Literature DB >> 8118603

Possible association of p53 overexpression and mutation with high-grade chondrosarcoma.

Y Dobashi1, H Sugimura, A Sato, T Hirabayashi, H Kanda, T Kitagawa, N Kawaguchi, T Imamura, R Machinami.   

Abstract

Overexpression and point mutation of the p53 protein/gene was investigated in a series of chondrosarcoma by an immunohistochemical approach, and direct sequencing of the genomic DNA, respectively. In 2 of the 16 cases studied, both of which were high grade chondrosarcomas (grade III), immunodetectable p53 was identified. Histologically, one was ordinary type and the other a clear cell variant. However, no positivity was observed in the other cases including nine of low grade, ordinary type, three of low grade, clear cell type, and two of extraskeletal myxoid chondrosarcoma. Direct sequencing, following polymerase chain reaction amplification of exons 5-9 of the p53 gene in 14 cases, in which fresh materials were available, successfully demonstrated base substitution mutations in only two cases with detectable p53 overexpression on immunohistochemistry. Their details were GTC (valine) to TTC (phenylalanine) at codon 157 in exon 5, and CGT (arginine) to CAT (histidine) at codon 273 in exon 8. No mutation was detected in the other 12 cases which were negative for p53 immunostaining. These findings strongly suggest that p53 mutation plays a crucial role in the biologically aggressive subtype, and possibly in the process of tumor progression in human chondrosarcoma.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8118603

Source DB:  PubMed          Journal:  Diagn Mol Pathol        ISSN: 1052-9551


  9 in total

1.  Gains, losses, and amplifications of DNA sequences evaluated by comparative genomic hybridization in chondrosarcomas.

Authors:  M L Larramendy; M Tarkkanen; J Valle; A H Kivioja; H Ervasti; E Karaharju; T Salmivalli; I Elomaa; S Knuutila
Journal:  Am J Pathol       Date:  1997-02       Impact factor: 4.307

2.  p53 gene mutations in soft-tissue sarcomas--correlations with p53 immunohistochemistry and DNA ploidy.

Authors:  R Schneider-Stock; K Radig; Y Oda; W Mellin; J Rys; A Niezabitowski; A Roessner
Journal:  J Cancer Res Clin Oncol       Date:  1997       Impact factor: 4.553

Review 3.  TP53 in bone and soft tissue sarcomas.

Authors:  Elizabeth Thoenen; Amanda Curl; Tomoo Iwakuma
Journal:  Pharmacol Ther       Date:  2019-07-02       Impact factor: 12.310

4.  Gadd45β expression in chondrosarcoma: a pilot study for diagnostic and biological implications in histological grading.

Authors:  Michihisa Zenmyo; Akihide Tanimoto; Harutoshi Sakakima; Masahiro Yokouchi; Satoshi Nagano; Takuya Yamamoto; Yasuhiro Ishido; Setsuro Komiya; Kosei Ijiri
Journal:  Diagn Pathol       Date:  2010-10-13       Impact factor: 2.644

5.  The nuclear factor of activated T cells (NFAT) transcription factor NFATp (NFATc2) is a repressor of chondrogenesis.

Authors:  A M Ranger; L C Gerstenfeld; J Wang; T Kon; H Bae; E M Gravallese; M J Glimcher; L H Glimcher
Journal:  J Exp Med       Date:  2000-01-03       Impact factor: 14.307

Review 6.  Chondrosarcoma-from Molecular Pathology to Novel Therapies.

Authors:  Agnieszka E Zając; Sylwia Kopeć; Bartłomiej Szostakowski; Mateusz J Spałek; Michał Fiedorowicz; Elżbieta Bylina; Paulina Filipowicz; Anna Szumera-Ciećkiewicz; Andrzej Tysarowski; Anna M Czarnecka; Piotr Rutkowski
Journal:  Cancers (Basel)       Date:  2021-05-14       Impact factor: 6.639

7.  Chondrosarcoma of the spine: a rare case with unusual presentation.

Authors:  John Panelos; Spyridon Voulgaris; Evangelos Michos; Michael Doukas; Konstantinos Charalabopoulos; Anna Batistatou
Journal:  Diagn Pathol       Date:  2006-10-30       Impact factor: 2.644

8.  Prognostic markers in chondrosarcoma: evaluation of cell proliferation and of regulators of the cell cycle.

Authors:  S P Scully; L J Layfield; J M Harrelson
Journal:  Sarcoma       Date:  1997

9.  The molecular pathogenesis of dedifferentiated chondrosarcoma.

Authors:  Akio Sakamoto
Journal:  Indian J Orthop       Date:  2014-05       Impact factor: 1.251

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.